Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Publisher： Karger

E-ISSN： 1423-0194|97|4|347-354

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.97, Iss.4, 2013-05, pp. : 347-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

By  

Neuroendocrinology, Vol. 93, Iss. 3, 2011-02 ,pp. : 189-196

Karger

Access to resources Recommend Favorite

Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

By  

Neuroendocrinology, Vol. 99, Iss. 2, 2014-04 ,pp. : 108-117

Karger

Access to resources Recommend Favorite

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

By  

Neuroendocrinology, Vol. 103, Iss. 5, 2015-06 ,pp. : 432-439

Karger

Access to resources Recommend Favorite

Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 47-50

Karger

Access to resources Recommend Favorite

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

By  

Neuroendocrinology, Vol. 102, Iss. 1-2, 2015-03 ,pp. : 18-25

Karger

Access to resources Recommend Favorite